Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing
Authors:
- Beata ChałupczyńskaBCBeata Chałupczyńska
- Elżbieta CiaraECElżbieta Ciara
- Paulina Halat-WolskaPHPaulina Halat-Wolska
- Agnieszka PollakAPAgnieszka Pollak
- Piotr StawińskiPSPiotr Stawiński
- Dorota JurkiewiczDJDorota Jurkiewicz
- Dorota Piekutowska-AbramczukDPDorota Piekutowska-Abramczuk
- Marzena GawlikMGMarzena Gawlik
- Justyna PietrasikJPJustyna Pietrasik
- Agata CieślikowskaACAgata Cieślikowska
- Dorota WicherDWDorota Wicher
- Agata UlatowskaAUAgata Ulatowska
Open Access
Abstract
Introduction: Epilepsy syndromes show marked clinical and genetic heterogeneity, with numerous functionally diverse genes involved in their etiology. Next-generation sequencing (NGS) has facilitated the identification of many monogenic epilepsy syndromes and enables earlier, more accurate diagnosis in pediatric patients. Materials and Methods: This study analyzes the molecular profiles of 87 pediatric patients with various forms of epilepsy in whom pathogenic or likely pathogenic variants were identified. Next-generation sequencing (NGS) using multi-gene epilepsy panels or whole-exome sequencing (WES) was performed. Results: A total of 88 pathogenic or likely pathogenic variants were detected in 48 epilepsy-related genes; 30 variants occurred de novo. SCN1A and KCNQ2 were the most frequent contributors (12.6% and 9.2%, respectively). The highest percentage of positive diagnoses (48%) was observed in patients with developmental and epileptic encephalopathy (DEE), with variants identified in genes including ALG13, ATP1A2, CACNA1A, CDKL5, CHD2, GABRG2, ITPA, KCNQ2, PCDH19, SCN1A, SCN2A, SCN3A, SCN8A, SMC1A, SPTAN1, STXBP1, and UBA5. Pathogenic variants in ANKRD11 were found in four patients with KBG syndrome, while other genes appeared sporadically. Conclusions: Targeted massively parallel sequencing is an effective diagnostic tool for pediatric epilepsy. The presence of numerous single-case findings highlights the high genetic heterogeneity of epilepsy. This approach enabled more precise diagnoses that would not have been achieved through clinical evaluation alone, underscoring the importance of genetic testing for prognosis and treatment planning in pediatric patients with unexplained epilepsy.Keywords
Funding Information
- Instytut Pomnik - Centrum Zdrowia Dziecka (M39/19)
- MEiN (7071/IB/SN/2020)
- MEiN (7088/II-KDM/SN/2020)
This publication has 59 references indexed in Scilit:
- Characterization of 13 Novel Genetic Variants in Genes Associated with Epilepsy: Implications for Targeted Therapeutic StrategiesMolecular Diagnosis & Therapy, 2024
- Utility of Exome Sequencing for Diagnosis in Unexplained Pediatric-Onset EpilepsyJAMA Network Open, 2023
- Genetic Diagnosis Impacts Medical Management for Pediatric EpilepsiesPediatric Neurology, 2022
- Genetic testing and counseling for the unexplained epilepsies: An evidence‐based practice guideline of the National Society of Genetic CounselorsJournal of Genetic Counseling, 2022
- Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsyEpilepsia Open, 2019
- PCDH19-related epilepsy in a male with Klinefelter syndrome: Additional evidence supporting PCDH19 cellular interference disease mechanismEpilepsy Research, 2018
- Pharmacogenomics in epilepsyNeuroscience Letters, 2018
- Diagnostic Yield From 339 Epilepsy Patients Screened on a Clinical Gene PanelPediatric Neurology, 2017
- Diagnostic Yield of Epilepsy Panels in Children With Medication-Refractory EpilepsyPediatric Neurology, 2016
- Mutations and deletions in PCDH19 account for various familial or isolated epilepsies in femalesHuman Mutation, 2010